BioMarin Pharmaceutical has been granted an accelerated assessment of its hemophilia A gene therapy valoctocogene roxaparvovec by the European Medicines Agency. An opinion from the EMA's Committee for Medicinal Products for Human Use is expected before July 2022.
EMA accelerates review of hemophilia A gene therapy
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.